Table 3 Microbiological outcomes
End Point | No. success (%) | Monotherapy (n = 79) | Combination therapy (n = 60) | P-value |
|---|---|---|---|---|
Overall success, no. (%) | 128 (92.1) | 70 (88.6) | 58 (96.7) | 0.11 |
Success per pathogen | ||||
Streptococcus pneumoniae (n = 50) | 48 | 31/32 (96.9) | 17/18 (94.4) | 1 |
Haemophilus influenzae (n = 29) | 27 | 20/21 (95.2) | 7/8 (87.5) | 0.48 |
Pseudomonas aeruginosa (n = 18) | 16 | 1/3 (33.3) | 15/15 (100) | 0.01 |
Acinetobacter baumanii (n = 12) | 8 | 1/5 (20.0) | 7/7 (100) | 0.01 |
Stenotrophomonas maltophilia (n = 10) | 9 | 5/6 (100) | 4/4 (100) | 1 |
Staphylococcus aureus (n = 8) | 8 | 4/4 (100) | 4/4 (100) | 1 |
Escherichia coli (n = 6) | 6 | 4/4 (100) | 2/2 (100) | 1 |
Moraxella catarrhalis (n = 6) | 6 | 4/4 (100) | 2/2 (100) | 1 |